PKM and hepatocellular carcinoma: It has been discovered that inhibiting pyruvate kinase M2 (PKM2), which plays a crucial role in the glycolytic pathway by catalyzing the final step of glycolysis, can restore sensitivity of HCC cells to sorafenib therapy [47, 48].